切换至 "中华医学电子期刊资源库"

中华细胞与干细胞杂志(电子版) ›› 2021, Vol. 11 ›› Issue (01) : 34 -39. doi: 10.3877/cma.j.issn.2095-1221.2021.01.005

所属专题: 文献

论著

血管内皮抑制素联合调强放疗对老年中晚期非小细胞肺癌的临床应用价值研究
杨娜1, 孙毅2,(), 迪丽努尔·尼加提1   
  1. 1. 830000 乌鲁木齐,新疆维吾尔自治区人民医院放疗一科
    2. 830000 乌鲁木齐,新疆维吾尔自治区人民医院肿瘤中心
  • 收稿日期:2020-04-22 出版日期:2021-02-01
  • 通信作者: 孙毅
  • 基金资助:
    吴阶平医学基金会临床科研专项资助(320.6799.1143)

Exploration of the clinical value of endostatin combined with intensity-modulated radiotherapy in elderly patients with advanced non-small cell lung cancer

Na Yang1, Yi Sun2,(), Nijiati Dilinuner·1   

  1. 1. Department of Radiotherapy, Xinjiang Uygur Autonomous Region People's Hospital, Urumqi 830000, China
    2. Cancer Center, Xinjiang Uygur Autonomous Region People's Hospital, Urumqi 830000, China
  • Received:2020-04-22 Published:2021-02-01
  • Corresponding author: Yi Sun
引用本文:

杨娜, 孙毅, 迪丽努尔·尼加提. 血管内皮抑制素联合调强放疗对老年中晚期非小细胞肺癌的临床应用价值研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2021, 11(01): 34-39.

Na Yang, Yi Sun, Nijiati Dilinuner·. Exploration of the clinical value of endostatin combined with intensity-modulated radiotherapy in elderly patients with advanced non-small cell lung cancer[J/OL]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2021, 11(01): 34-39.

目的

探讨血管内皮抑制素联合调强放疗在老年中晚期非小细胞肺癌(NSCLC)中的放疗增敏作用及对T细胞、NK细胞的影响。

方法

选取2015年3月至2016年8月新疆维吾尔自治区人民医院NSCLC患者106例,依据简单随机数字表法分为对照组(采取调强放疗)与研究组(在对照组基础上使用血管内皮抑制素),每组53例。分析两组临床疗效、治疗前后NK细胞、T细胞水平、血清肿瘤标志物水平、EPO mRNA、EPO-R mRNA水平、毒副反应,随访3年后统计两组生存情况[中位总生存期(OS)、中位无进展生存期(PFS)]。两组比较采用独立样本t检验,组内治疗前后比较采用配对t检验,临床疗效、毒副反应发生率等采用χ2检验。

结果

对照组肿瘤控制率低于研究组(69.81﹪比86.79﹪)(P < 0.05);与治疗前比较,两组治疗后NK细胞、CD3+、CD4+、CD4+/CD8+水平,血清CA199、CA125、CEA、CY211水平,EPO mRNA、EPO-R mRNA水平均降低,CD8+水平增高,差异有统计学意义(P均< 0.05);与对照组治疗后比较,研究组治疗后NK细胞[(8.01±1.64)﹪比(10.44±2.13)﹪]、CD3+[(53.51±6.02)﹪比(59.33±5.15)﹪]、CD4+[(32.31±4.01)﹪比(36.40±3.86)﹪]、CD4+/CD8+[(0.94±0.28)﹪比(1.23±0.30)﹪],中位PFS(5个月比8个月)、中位OS(18个月比23个月)升高,CD8+[(34.22±3.08)﹪比(29.56±2.50)﹪],CA199[(35.20±4.46) kU/ L比(30.15± 4.14) kU/L]、CA125[(34.91±6.03)kU/L比(29.77±5.30)kU/L]、CEA[(22.50±3.97)μg/ L比(17.97±4.10)μg/L]、CY211[(7.19±2.01) μg/L比(4.56± 1.34) μg/ L],EPO mRNA水平(0.85±0.08比0.80±0.06)、EPO-R mRNA水平(0.88±0.09比0.81±0.08)降低,差异具有统计学意义(P均<0.05);与对照组比较,研究组血红蛋白减少、肝肾功能损伤、恶心呕吐、中性粒细胞减少发生率之间比较差异无统计学意义(P > 0.05)。

结论

联合采取调强放疗及血管内皮抑制素治疗老年中晚期NSCLC,可有效提高肿瘤控制率,改善患者生存状况,可能是因其能降低血清肿瘤标志物水平,减轻对免疫功能的影响,调节EPO mRNA、EPO-R mRNA,且具有安全性。

Objective

To investigate the radiosensitization effect of endostatin combined with intensity-modulated radiotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC) and its effect on T cells and natural killer (NK) cells.

Methods

A total of 106 patients with NSCLC in our hospital from March 2015 to August 2016 were selected and divided into a study group and a control group according to a simple random number table method, 53 cases in each group. The control group took intensity-modulated radiotherapy, and the study group took endostatin on the basis of the control group. The clinical efficacy, levels of NK cells and T cells, serum tumor marker levels, erythropoieth (EPO) mRNA, EPO-receptor mRNA levels before and after treatment, toxic and side effects were counted in the two groups. After 3 years of follow-up, the survival [median overall survival (OS) , median progression-free survival (PFS) ]of the two groups was counted.

Results

The tumor control rate of the study group (86.79﹪) was higher than that of the control group (69.81﹪) (P < 0.05) ; after treatment, the NK cells, CD3+, CD4+, CD4+/CD8+ in the two groups were lower than before treatment, and CD8+ was higher than before treatment. However, NK cells (10.44±2.13) ﹪, CD3+ (59.33±5.15) ﹪, CD4+ (36.40±3.86) ﹪, and CD4+/CD8+ (1.23±0.30) in the study group were higher than those in the control group, CD8+ (29.56±2.50) ﹪ was lower than the control group (P < 0.05) ; after treatment, the serum levels of CA199, CA125, CEA and CY211 in the two groups were lower than before treatment. And the CA199 (30.15±4.14) kU/L, CA125 (29.77±5.30) kU/ L, CEA (17.97±4.10) μg/L, CY211 (4.56±1.34) μg/L of the study group were lower than those of the control group (P < 0.05) ; after treatment, the levels of EPO mRNA and EPO-R mRNA in the two groups were lower than before treatment. EPO mRNA (0.80±0.06) and EPO-R mRNA (0.81±0.08) in the study group were lower than those in the control group (P < 0.05) ; the incidence of hemoglobin reduction, liver and kidney function damage, vomiting and nausea, neutropenia between the study group and the control group were not significantly different (P > 0.05) ; the median PFS of 8 months and the median OS of 23 months in the study group were higher than those in the control group (P < 0.05) .

Conclusion

Combined intensity-modulated radiotherapy and endostatin for the treatment of middle-late advanced NSCLC in the elderly can effectively improve the tumor control rate and the survival status of patients, which may be because it can reduce the level of serum tumor markers, reduce the impact on immune function, regulate EPO mRNA and EPO-R mRNA, and have safety.

表1 引物序列信息
表2 对照组和研究组患者一般资料比较
表3 对照组和研究组治疗后肿瘤控制率比较[ n (﹪)]
表4 对照组和研究组治疗前后T细胞、NK细胞水平比较(﹪, ± s
表5 对照组和研究组治疗前后血清肿瘤标志物水平比较( ± s
表6 对照组和研究组治疗前后EPO mRNA、EPO-R mRNA水平比较( ± s
表7 对照组和研究组治疗期间毒副反应发生率比较
图1 对照组和研究组中位总生存期和中位无进展生存期比较
1
Koshy M, Malik R, Spiotto M, et al. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy[J]. Lung cancer, 2017, 108(1):222-227.
2
倪千喜. 中央型非小细胞肺癌肿瘤体积与位置对调强放射治疗靶区剂量的影响[J]. 肿瘤学杂志, 2019, 25(7):634-636.
3
Zhao X, Su Y, You J, et al. Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects[J]. Oncotarget, 2016, 7(38):62619-62626.
4
中华医学会呼吸病学分会肺癌学组,中国肺癌防治联盟专家组. 肺部结节诊治中国专家共识[J]. 中华结核和呼吸杂志, 2015, 38(4):249-254.
5
杨学宁,吴一龙. 实体瘤治疗疗效评价标准——RECIST[J]. 循证医学, 2004, 4(2):85-90.
6
潘宏铭, 耿宝琴. 肿瘤化疗的毒副反应和防治[M]. 上海:上海科学技术出版社, 2001:303-307.
7
Baker S, Dahele M, Lagerwaard FJ, et al. A critical review of recent developments in radiotherapy for non-small cell lung cancer[J]. Radiat Oncol, 2016, 11(1):115.
8
熊慧如. 调强放疗联合化疗治疗局部晚期非小细胞肺癌临床疗效分析[J]. 肿瘤基础与临床, 2019, 32(2):120-122.
9
Ling DC, Hess CB, Chen AM, et al.Comparison of toxicity between intensity modulated radiation therapy and 3-dimensional conformal radiation therapy for locally advanced non-small cell lung cancer[J]. Clin lung cancer, 2016, 17(1):18-23.
10
王院霞,刘峰,郑巧平, 等. 调强放疗与立体定向体部放疗同步化疗对Ⅲ期非小细胞肺癌患者免疫功能及血清细胞因子的影响[J]. 癌症进展, 2019, 17(19):2288-2291.
11
Jia L, Lu XA, Liu G, et al. Endostatin sensitizes p53-deficient non-small-cell lung cancer to genotoxic chemotherapy by targeting DNA-dependent protein kinase catalytic subunit[J]. J Pathol, 2017, 243(2):255-266.
12
张敏,段爱雄,江启安.血管内皮抑制素联合培美曲塞及顺铂对晚期肺腺癌患者相关肿瘤因子水平的影响[J].海南医学院学报,2017,23(20):2846-2849.
13
李德龙. 重组人血管内皮抑制素联合顺铂胸腔热灌注治疗对晚期非小细胞肺癌患者血清促红细胞生成及其受体水平的影响[J]. 中国药物与临床, 2019, 19(10):1697-1699.
[1] 郭倩男, 史嘉玮, 董念国. T细胞不同代谢方式在移植排斥反应中的研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 315-320.
[2] 杨慧, 郭丽娟, 冯晓丹, 李静, 黄成谋, 蔡兴锐, 覃英娇, 王远礼. 非小细胞肺癌铂类药物耐药mi RNA表达特征及预测分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 719-724.
[3] 赖淼, 景鑫, 李桂珍, 李怡. 非小细胞肺癌EGFR 突变亚型的临床病理和预后意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 731-737.
[4] 梁丽斯, 李洁, 贺帅, 来艳君, 刘铭, 张琳. MMP-9、MMP-2 及TLR4、HE4对非小细胞肺癌早期诊断意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 756-761.
[5] 张礼江, 沈玲佳, 施我大. 倾向性评分匹配分析奥希替尼对晚期NSCLC 预后的影响[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 820-822.
[6] 赵蒙蒙, 黄洁, 余荣环, 王葆青. 过表达小GTP酶Rab32抑制非小细胞肺癌细胞侵袭性生长[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 512-518.
[7] 张桂萍, 丘勇林, 湛绮婷, 孙乐栋. 晚期非小细胞肺癌血清Ape1/Ref-1对放射性肺损伤发生的预测意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 519-523.
[8] 韩晓宇, 李柯育, 赵志菲, 高建平. SNHG17过表达对非小细胞肺癌切除术预后的意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 543-547.
[9] 刘松, 张进召, 贾艳云. 帕博利珠单抗治疗晚期非小细胞肺癌反应降低与抗生素预处理的关系[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 553-557.
[10] 李多, 郝昭昭, 陈延伟, 南岩东. 血清PTX3表达与非小细胞肺癌骨转移的相关性分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 558-562.
[11] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[12] 张英信, 林婷, 张剑文. 构建靶向HLA-A2且表达PD-L1的CAR-Treg细胞及验证其对CD4+T细胞抑制作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 719-728.
[13] 孙婧婷, 李娜, 罗明辉, 高瑶瑶, 白义行, 朱国贞. 短链脂肪酸对小鼠缺血再灌注肾损伤的炎症及纤维化影响和作用机制研究[J/OL]. 中华肾病研究电子杂志, 2024, 13(04): 181-187.
[14] 段伟, 刘飞, 许光源, 程宇豪, 陈星. 食管癌调强放疗计划剂量学参数差异对放射性肺炎发生及严重程度的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(04): 320-324.
[15] 蔡剑桥, 蒋雷. 单孔胸腔镜与开胸双袖式肺叶切除治疗非小细胞肺癌对比[J/OL]. 中华胸部外科电子杂志, 2024, 11(04): 225-230.
阅读次数
全文


摘要